Scientists from the University of Eastern Finland (Finland) and the University of Oulu (Finland) have published a study that demonstratesshows serum neurofilament levels could be used as a biomarker to discriminate frontotemporal dementia from psychiatric disorders.
Scientists from the University of Utah (UT, USA) report a novel miRNA biomarker -based strategy that could improve melanoma diagnosis.
A recent study reports a new biomarker panel, comprised of 28 physical and molecule measures, that could successfully confirm the diagnosis of warzone-related post-traumatic stress disorder (PTSD) with 77% accuracy.
In a new study, researchers from Osaka University (Japan) have demonstrated that measuring methylation of microRNA could accurately distinguish individuals with early pancreatic cancer from healthy controls.
Researchers have discovered unique populations of neurons in the spinal cords of patients who died of amyotrophic lateral sclerosis that could be utilized as potential drug targets.
A multiplex HRMS assay for quantifying selected human plasma bile acids as candidate OATP biomarkers
This preliminary communication from Bioanalysis discusses the application of selected bile acids in plasma as endogenous probes for assessing drug–drug interactions involving hepatic drug transporters such as the organic anion-transporting polypeptides.
In this interview, Hanna Ritzén (Mercodia; Uppsala, Sweden) provides an insight into her recent article on classification of commercial LBA kits for biomarkers, and why this area of bioanalysis is important.
In this interview, Stephanie Traub (Cancer Research UK; London, UK) discusses her work as a biomarker specialist and the challenges she faces when developing biomarker strategies.
In this editorial Sally Fischer (Genentech; CA, USA) explores ligand binding assay technologies: how to match the right tool to the bioanalytical challenge.
Recommendations for classification of commercial LBA kits for biomarkers in drug development from the GCC for bioanalysis
In this White Paper from Bioanalysis the authors highlight the need the bioanalytical community has for commercial kits able to be used for regulated drug development.